Uploaded July 2026 | Updated September 2026, 1 week ago

---

Alex Zhavoronkov has summarized the common approaches into three categories:

1) Both the target and the molecule are highly novel
2) The novelty of both the target and the molecule is moderate
3) The target is relatively nonnovel, but the molecule itself is highly innovative. Each of these approaches has its own merits.

The question is: as an AI-driven pharmaceutical company, how do we weigh up these options?

And why do we make such choices? The answer lies in this video.

#openclaw #AIdrivenpharma #Openclaw #novelty #target